Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome (Q41084855)

26 September 2017

1 reference

title

Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

26 September 2017

1 reference

1 reference

Holte J

1

1 reference

26 September 2017

1 April 1996

1 reference

Bailliere's clinical endocrinology and metabolism

26 September 2017

1 reference

26 September 2017

10

1 reference

26 September 2017

221-247

1 reference

26 September 2017

2

1 reference

Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism.

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Testosterone concentrations in women and men with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Hyperandrogenicity in women--a prediabetic condition?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Body composition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin and insulin-like growth factor-I responsiveness in polycystic ovarian syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Increased circulating levels of immunoreactive beta-endorphin in polycystic ovary syndrome is not caused by increased pituitary secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance in nonobese patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Acanthosis nigricans in obese women with the polycystic ovary syndrome: disease spectrum not distinct entity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Impaired insulin degradation in a patient with insulin resistance and acanthosis nigricans

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effect of fatty acids on glucose production and utilization in man

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Hormonal changes in patients with polycystic ovarian disease after ovarian electrocautery or pituitary desensitization

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The insulin-like growth factor system in normal and abnormal human ovarian follicle development

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade in the polycystic ovary syndrome with acanthosis nigricans

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance, secretion, and metabolism in users of oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Lack of predictive value of HbA1 for impaired glucose tolerance in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Bulimia nervosa and polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Androgen-estrogen metabolism in women with upper body versus lower body obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Response of plasma beta-endorphin and insulin to oral glucose tolerance test in non-obese women with polycystic ovaries.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effect of naloxone on plasma insulin, insulin-like growth factor I, and its binding protein 1 in patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Corticotropin-releasing hormone induces an exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Longitudinal Study on the Establishment of Insulin Resistance in Hypothalamic Obese Mice*

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Aromatase activity in human adipose tissue stromal cells: effect of growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Polycystic ovary syndrome and bulimia**Supported by the Special Trustees of St. George’s Hospital and the Priory Hospital, London, United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin-like growth factor-I stimulates the expression of 3 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid in ovarian theca-interstitial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin-like growth factor-I selectively stimulates cholesterol side-chain cleavage expression in ovarian theca-interstitial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Muscle fiber composition and capillary density in women and men with NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Cortisol secretion in relation to body fat distribution in obese premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effects of insulin incubation on insulin binding, glucose transport, and insulin degradation by isolated rat adipocytes. Evidence for hormone-induced desensitization at the receptor and postreceptor level

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Characterization of 24-h cortisol release in obese and non-obese hyperandrogenic women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance--mechanisms, syndromes, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Metabolic regulation of androgen production by human thecal cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Defects in beta-cell function in functional ovarian hyperandrogenism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance in patients with polycystic ovaries: its relationship to body weight and androgen levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The relative contribution of androgens and insulin in determining abdominal body fat distribution in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The interconversion and aromatization of androgens by human adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Induction of insulin resistance by androgens and estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The gonadotropic function of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Glucocorticoid hormone binding to human adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Steroid hormone receptors in human adipose tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Elevated production and metabolic clearance rates of androgens in morbidly obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The influence of androgens on insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Insulin resistance in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Pancreatic beta-cell growth and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

The relation between clinical manifestations of polycystic ovary syndrome and beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

Endocrine comparison of obese menstruating and amenorrheic women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2896%2980085-1

7 January 2021

10.1016/S0950-351X(96)80085-1

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8773746